Skip to content

Validation of the Effect of Changxinwei Shanlexing Product Combination on Improving Gastrointestinal Health

Validation of the Effect of Changxinwei Shanlexing Product Combination on Improving Gastrointestinal Health

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111688
Enrollment
Unknown
Registered
2025-11-04
Start date
2025-06-10
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic gastritis (non atrophic)

Interventions

Group A (combined intervention group):Received intervention with Changxinwei oral liquid and Shanlexing probiotic solid beverage
Group B (positive control group) :Received intervention with Changxinwei oral liquid combined with product 2 placebo
Group C (single intervention group) :Received placebo intervention with Shanle Xing probiotic solid beverage combined with product 1

Sponsors

Beijing University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) People aged 18 to 65. (2) Meets the diagnostic criteria for chronic gastritis (non atrophic). (3) Be aware of and understand the content of this study, and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating women, individuals with allergies, and those who are allergic to this sample. (2) Secondary chronic gastritis. (3) Patients with severe cardiovascular, cerebrovascular, hepatic, renal, and hematopoietic system diseases, as well as psychiatric disorders, are included in the merger. (4) Frequent medication use, alcohol addiction, smoking, and participation in other experiments within the past 4 weeks. (5) Used drugs known to be harmful to gastrointestinal function within 3 months. (6) Symptoms and signs are classified as severe cases. (7) The results of gastroscopy examination were determined by professional physicians to be moderate to severe damage to the gastric mucosa. (8) Patients with severe digestive system ulcers. (9) Individuals who are currently taking other therapeutic medications or undergoing other treatments. (10) Those who have not taken the sample according to regulations, are unable to determine its efficacy, or have incomplete information that affects efficacy or safety assessment.

Design outcomes

Primary

MeasureTime frame
Classification of Symptoms in Human Food Trial Experiment;Observation of functional indicators and signs;gastroscope;

Secondary

MeasureTime frame
Quantitative Grading Table of Traditional Chinese Medicine Symptoms;SF-36 scale;GSRS scale;gastrin;motilin;cholecystokinin;pepsinogen;

Countries

China

Contacts

Public ContactLi Lingru

Beijing University of Chinese Medicine

700435@bucm.edu.cn+86 134 2609 6071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026